David D. Chang - 25 Jan 2024 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
President and CEO, Director
Signature
/s/Earl Douglas, Attorney-in-Fact
Issuer symbol
ALLO
Transactions as of
25 Jan 2024
Transactions value $
$0
Form type
4
Filing time
31 Jan 2024, 17:42:37 UTC
Previous filing
24 Mar 2023
Next filing
18 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $0 +318K +7.57% $0.00 4.51M 25 Jan 2024 Direct F1
holding ALLO Common Stock 1.2M 25 Jan 2024 See footnote F2
holding ALLO Common Stock 856K 25 Jan 2024 See footnote F3
holding ALLO Common Stock 856K 25 Jan 2024 See footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to buy) Award $0 +1.12M $0.00 1.12M 25 Jan 2024 Common Stock 1.12M $3.20 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1492 shares of the Issuer's common stock acquired by the reporting person on September 15,2023 pursuant to an employee stock purchase program.
F2 Securities held in the name of the Chang 2006 Family Trust
F3 Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
F4 Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
F5 1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter.